Mingyuan Medicare Development Acquires Shanghai Kang Pei Bio-Medical
This article was originally published in PharmAsia News
Following an agreement in October, Mingyuan Medicare Development has completed the acquisition of 75 percent stake in Shanghai Kang Pei Bio-Medical with RMB 310 million in cash. Together with three subsidiaries and two joint-venture firms, Kang Pei Bio-Medical focuses on providing medical diagnosis, check-ups and health care evaluation services to China's customers, including Mingyuan Medicare's affiliated companies for the past two years. Kang Pei Bio-Medical has set up 12 health care centers in Shanghai, Tianjin, Chengdu and Taiyuan; these facilities annually service more than 400,000 customers. (Click here for more - Chinese Language)
You may also be interested in...
The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.